CN102648412A - 5-fu的检测方法 - Google Patents

5-fu的检测方法 Download PDF

Info

Publication number
CN102648412A
CN102648412A CN2010800415495A CN201080041549A CN102648412A CN 102648412 A CN102648412 A CN 102648412A CN 2010800415495 A CN2010800415495 A CN 2010800415495A CN 201080041549 A CN201080041549 A CN 201080041549A CN 102648412 A CN102648412 A CN 102648412A
Authority
CN
China
Prior art keywords
sample
patient
fluorouracil
blood
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800415495A
Other languages
English (en)
Chinese (zh)
Inventor
S·J·萨拉莫内
B·洛
C·科尔文
M·奥弗菲尔德
H·麦克劳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myrexis Inc
Original Assignee
Myriad Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Pharmaceuticals Inc filed Critical Myriad Pharmaceuticals Inc
Publication of CN102648412A publication Critical patent/CN102648412A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150015—Source of blood
    • A61B5/15003—Source of blood for venous or arterial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
    • A61B5/150236—Pistons, i.e. cylindrical bodies that sit inside the syringe barrel, typically with an air tight seal, and slide in the barrel to create a vacuum or to expel blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
    • A61B5/150244—Rods for actuating or driving the piston, i.e. the cylindrical body that sits inside the syringe barrel, typically with an air tight seal, and slides in the barrel to create a vacuum or to expel blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150351—Caps, stoppers or lids for sealing or closing a blood collection vessel or container, e.g. a test-tube or syringe barrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
    • A61B5/150381—Design of piercing elements
    • A61B5/150389—Hollow piercing elements, e.g. canulas, needles, for piercing the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
    • A61B5/150381—Design of piercing elements
    • A61B5/150503—Single-ended needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
    • A61B5/150534—Design of protective means for piercing elements for preventing accidental needle sticks, e.g. shields, caps, protectors, axially extensible sleeves, pivotable protective sleeves
    • A61B5/150694—Procedure for removing protection means at the time of piercing
    • A61B5/150717—Procedure for removing protection means at the time of piercing manually removed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
    • A61B5/154—Devices using pre-evacuated means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Manufacturing & Machinery (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
CN2010800415495A 2009-07-17 2010-07-19 5-fu的检测方法 Pending CN102648412A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22658909P 2009-07-17 2009-07-17
US61/226,589 2009-07-17
US32424110P 2010-04-14 2010-04-14
US61/324,241 2010-04-14
PCT/US2010/042485 WO2011009140A1 (en) 2009-07-17 2010-07-19 Method of assaying 5-fu

Publications (1)

Publication Number Publication Date
CN102648412A true CN102648412A (zh) 2012-08-22

Family

ID=43449866

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800415495A Pending CN102648412A (zh) 2009-07-17 2010-07-19 5-fu的检测方法

Country Status (9)

Country Link
US (1) US8440442B2 (enExample)
EP (2) EP3792634A3 (enExample)
JP (1) JP5863047B2 (enExample)
CN (1) CN102648412A (enExample)
AU (1) AU2010273964A1 (enExample)
BR (1) BR112012000873A2 (enExample)
CA (1) CA2768488A1 (enExample)
IN (1) IN2012DN01379A (enExample)
WO (1) WO2011009140A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166795A1 (en) * 2011-05-30 2012-12-06 String Therapeutics Inc. Methods and compositions for therapeutic drug monitoring and dosing by point-of-care pharmacokinetic profiling
JP2015502356A (ja) * 2011-11-30 2015-01-22 ウェルスタット ダイアグノスティクス，エルエルシー ５−ｆｕに関連するアッセイ、抗体、免疫原および組成物
US9075042B2 (en) * 2012-05-15 2015-07-07 Wellstat Diagnostics, Llc Diagnostic systems and cartridges
US10809264B2 (en) * 2014-05-29 2020-10-20 Siemens Healthcare Diagnostics Inc. Rare molecule detection
WO2018232031A1 (en) * 2017-06-14 2018-12-20 Epiphany La Undergarment padding
AR133242A1 (es) * 2023-07-13 2025-09-10 Processa Pharmaceuticals Inc Métodos de personalización del tratamiento contra el cáncer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105086A1 (en) * 2004-04-29 2005-11-10 Taiho Pharmaceutical Co., Ltd. Method for reducing gastrointestinal toxicity due to the administration of tegafur
CN101068549A (zh) * 2004-12-03 2007-11-07 阿迪赫里克斯技术公司 与5－fu和5－fu前药组合施用dpd抑制剂的方法
CN101333558A (zh) * 2007-06-29 2008-12-31 上海裕隆生物科技有限公司 5氟尿嘧啶药物敏感基因芯片检测试剂盒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225245A1 (en) * 1998-09-29 2007-09-27 Buchsbaum Donald J Viral vector driven mutant bacterial cytosine deaminase gene and uses thereof
ZA200701657B (en) * 2004-08-06 2008-09-25 Genentech Inc Assays and methods using biomarkers
US20060177883A1 (en) 2005-02-08 2006-08-10 Saladax Biomedical Inc. 5-Fluoro-uracil immunoassay

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105086A1 (en) * 2004-04-29 2005-11-10 Taiho Pharmaceutical Co., Ltd. Method for reducing gastrointestinal toxicity due to the administration of tegafur
CN101068549A (zh) * 2004-12-03 2007-11-07 阿迪赫里克斯技术公司 与5－fu和5－fu前药组合施用dpd抑制剂的方法
CN101333558A (zh) * 2007-06-29 2008-12-31 上海裕隆生物科技有限公司 5氟尿嘧啶药物敏感基因芯片检测试剂盒

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOSEPH BERTINO ET AL: "Highlights from:5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop", 《CLINICAL COLORECTAL CANCER》, 31 March 2007 (2007-03-31), pages 407 - 422, XP055033969, DOI: doi:http://dx.doi.org/10.1016%2FS1533-0028%2811%2970480-7 *

Also Published As

Publication number Publication date
JP2012533739A (ja) 2012-12-27
BR112012000873A2 (pt) 2019-11-05
US8440442B2 (en) 2013-05-14
WO2011009140A1 (en) 2011-01-20
EP2454589A4 (en) 2012-09-05
US20110034488A1 (en) 2011-02-10
EP3792634A3 (en) 2021-06-02
IN2012DN01379A (enExample) 2015-06-05
AU2010273964A1 (en) 2012-02-02
EP3792634A2 (en) 2021-03-17
EP2454589A1 (en) 2012-05-23
JP5863047B2 (ja) 2016-02-16
CA2768488A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
Craver et al. N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm
Sarray et al. Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition
Pai et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis
Guthikonda et al. Reticulated platelets and uninhibited COX‐1 and COX‐2 decrease the antiplatelet effects of aspirin
Soefje et al. Common toxicities of mammalian target of rapamycin inhibitors
Colkesen et al. The role of mean platelet volume in predicting thrombotic events
CN102648412A (zh) 5-fu的检测方法
US20200340066A1 (en) Diagnosing idh1 related subgroups and treatment of cancer
WO2009102986A1 (en) Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox1 inhibitor
Seetharam et al. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910. Na
WO2021247548A1 (en) Treatments for a sub-population of inflammatory bowel disease patients
Marx et al. Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients
EP3258923A1 (en) Methods and materials for assessing chemotherapy responsiveness and treating cancer
Aboul-Enein et al. Peripheral expression of hepcidin gene in Egyptian β-thalassemia major
WO2015077725A1 (en) Diagnosing idh1 related subgroups and treatment of cancer
JPH07504913A (ja) １６員環マクロライド型化合物を含む抗腫瘍活性を有する薬剤
Saif et al. Peripheral neuropathy exacerbation associated with topical 5-fluorouracil
HK40048825A (en) Method of assaying 5-fu
Chiang et al. Modulation of the anticancer activities of paclitaxel by Cremophor micelles
Pazmiño et al. Inhibition of human erythrocyte phenol‐O‐methyltransferase in uremia
CN110776521A (zh) 一种1,2,4-三唑-1,3,4-噻二唑类化合物及其应用
Asdie et al. Does insulin resistance correlate with routine blood examination? A review on erythrocytes of obese patients
RU2617392C2 (ru) Применение arry-520 для лечения рака у пациентов с низким уровнем акг
Anemia GENERAL CONCEPTS IN IRON-RELATED DISORDERS
Ouologuem et al. Loss of two-pore channel 2 enhances CD8+ T cell cytotoxicity and directly impairs tumour growth via MAPK axis in HCC

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120822